Doctor Panel Membership site
EN
IVD market in China
2025-01-22
What is IVD?
In Vitro Diagnostics (IVD) refers to products and services that are used outside the human body to obtain clinical diagnostic inform ation by testing human samples (various body fluids, cells, tissue samples, etc.) to determine diseases or body functions.
IVD market size growth slows down due to normalization of epidemics
China’s IVD market grew from 43 billion in 2016 to 119.7 billion in 2022.With the normalization of epidemic prevention and control, the demand for COVID-related tests has decreased, and the scale is estimated to be 120 billion in 2023, with growth leveling off.
* Source：医械会，深企头产业研究院
Immuno-diagnostic dominates the marketCLIA is the most dominant technology used in imm uno-diagnostic
Immuno-diagnostics, molecular diagnostics, and biochemical diagnostics ranked among the top three, with a market share of more than 70% or more.CLIA, in a rapid growth cycle, occupies an absolute advantage and is likely to drive a new round of techn ological innovation and market growth.
IVD type market share, 2022
Immuno-diagnostic market share, 2022
* Source：医械会，深企头产业研究院，中商产业研究院
With the improvement of domestic product technology and the promotion of VBP,the domestic rate in CLIA is expected to be accelerated
Restricted by the technical barriers of CLIA, in the domestic immuno-diagnostic market, foreign manufacturers such as Roche, Abbott, Beckman, Siemens, and others have been long-term dominant.With the pilot VBP of CLIA in Anhui Province in 2021 and the advancement of the second VBP in 2023, the domestic rate in CLIA is accelerating.
CLIA market share Top3, 2022
36%
20%
10%
CLIA VBP market share Top3, 2024
32%
14%
11%
* Source：https://zhuanlan.zhihu.com/p/16217730997
Please contact us for more information!
Contact
sales@cn.intage.com
We will provide you with a market research proposal.If you have any questions, we will contact you as soon as possible.